Brought to you by 
J&J buys Synthes for $21.7bn
04 May 2011
Executive Summary
Johnson & Johnson has made its largest acquisition to date via the purchase of public orthopedic device manufacturer Synthes Inc. for $21.7bn (CHF18.6bn). Shareholders will receive $182 per share (a 30% premium), of which $63.57 will be paid in cash and $118.07 in J&J common stock (almost 2 shares) as long as J&J’s shares stay between $60.20 and $69.26 during the 10-day trading period leading up to the close of the transaction.
Deal Industry
- Biotechnology
- Medical Devices
-
Medical Devices
- Biomaterials
- Implantable Devices
- Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J buys Synthes for $21.7bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice